Acurx Pharmaceuticals — Valuation, Funding & Investors

Recent changes

Sep 8, 2026Sep 8, 2026Acurx Pharmaceuticals Files S-1, Already Trades on Nasdaq Pulse story
Apr 29, 2026Apr 29, 2026Raised $4.6M SEC EDGAR Form D
20252025IPO $7.1 million SEC EDGAR

Funding History

2 events · sources dated per row

Date	Event	Amount	Valuation	Investors	Source
Apr 29, 2026	funding round	$4.6M	—		SEC EDGAR Form D
Jan 1, 2025	ipo	$7.1 million	—		Pulse story

Latest Pulse

Sep 8, 2026Acurx Pharmaceuticals Files S-1, Already Trades on NasdaqAcurx Pharmaceuticals, a Nasdaq-listed antibiotic developer trading as ACXP, filed a new S-1 that continues a 2026 pattern of small registered-direct offerings rather than a first-time listing.→

Coverage Timeline

newest first

Sep 8, 2026IPOAcurx Pharmaceuticals Files S-1, Already Trades on Nasdaq→

All Coverage

IPO· Sep 8, 2026

Acurx Pharmaceuticals Files S-1, Already Trades on Nasdaq

IPO

Acurx Pharmaceuticals Files S-1, Already Trades on Nasdaq

Acurx Pharmaceuticals, a Nasdaq-listed antibiotic developer trading as ACXP, filed a new S-1 that continues a 2026 pattern of small registered-direct offerings rather than a first-time listing.

Sep 8, 2026DEEP DIVE

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics

Sources & methodologyshow

Where these figures come from

SEC EDGARprimary source1 fact
SEC EDGAR Form Dprimary source1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction